OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Rating of “Moderate Buy” from Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $11.8125.

A number of equities research analysts recently weighed in on OPRX shares. Wall Street Zen raised OptimizeRx from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a research report on Friday, August 8th. Stifel Nicolaus lifted their target price on OptimizeRx from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. JMP Securities lifted their target price on OptimizeRx from $14.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Monday, August 11th. Finally, Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a report on Tuesday, May 13th.

Institutional Investors Weigh In On OptimizeRx

A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in OptimizeRx by 670.3% during the 4th quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company’s stock worth $291,000 after buying an additional 52,169 shares in the last quarter. Geode Capital Management LLC lifted its holdings in OptimizeRx by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company’s stock worth $1,948,000 after buying an additional 4,821 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after buying an additional 2,797 shares in the last quarter. Barclays PLC lifted its holdings in OptimizeRx by 13.5% during the 4th quarter. Barclays PLC now owns 30,574 shares of the company’s stock worth $148,000 after buying an additional 3,640 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in OptimizeRx during the 4th quarter worth $178,000. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Stock Down 4.2%

OPRX stock opened at $16.86 on Friday. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $18.22. The company has a market cap of $313.09 million, a PE ratio of -31.22, a price-to-earnings-growth ratio of 5.86 and a beta of 1.33. The business’s 50-day simple moving average is $13.83 and its 200 day simple moving average is $10.23. The company has a quick ratio of 2.82, a current ratio of 2.57 and a debt-to-equity ratio of 0.21.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.